AFX — Carl Zeiss Meditec AG Income Statement
0.000.00%
Last trade - 00:00
- €8.97bn
- €9.20bn
- €2.09bn
- 71
- 10
- 96
- 63
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,459 | 1,335 | 1,647 | 1,903 | 2,089 |
Cost of Revenue | |||||
Gross Profit | 832 | 746 | 967 | 1,128 | 1,206 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,195 | 1,158 | 1,273 | 1,506 | 1,741 |
Operating Profit | 265 | 178 | 374 | 397 | 348 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 230 | 179 | 339 | 403 | 413 |
Provision for Income Taxes | |||||
Net Income After Taxes | 161 | 123 | 238 | 296 | 292 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 160 | 122 | 236 | 294 | 290 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 160 | 122 | 236 | 294 | 290 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.83 | 1.42 | 2.62 | 3.29 | 3.25 |
Dividends per Share |